Telix reaffirms FY 2026 revenue guidance of US$950 million-US$970 million

Telix

Telix

TLX

0.00
  • Telix reaffirmed FY 2026 revenue guidance of US$950 million to US$970 million.
  • Outlook follows Q1 2026 unaudited group revenue of US$230 million, up 11% from Q4 2025.
  • Precision Medicine Q1 revenue reached US$186 million, up 16% quarter-over-quarter, supported by growth in Illuccix and Gozellix.
  • R&D spending guidance was reiterated at US$200 million to US$240 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604061937PRIMZONEFULLFEED9684957) on April 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.